ELI LILLY AND COMPANY Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
ELI LILLY AND COMPANY (LLY) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $8.95 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $8.95B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $5.28B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $7.27B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $9.79B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations as first filed |
|---|---|---|
| 2026-06-30 | $8.95B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $5.28B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $7.27B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $9.79B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $3.38B 10-Q · filed 2026-08-05 | $3.38B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.09B 10-Q · filed 2026-04-30 | $3.09B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $3.27B 10-Q · filed 2026-08-05 | $3.27B 10-K · filed 2025-02-19 |
| 2024-09-30 | $3.37B 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $3.22B 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $2.46B 10-Q · filed 2025-05-01 | |
| 2023-12-31 | $2.82B 10-K · filed 2026-02-12 | $2.82B 10-K · filed 2024-02-21 |
| 2023-09-30 | $2.38B 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $2.69B 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $3.55B 10-Q · filed 2024-04-30 | |
| 2022-12-31 | $2.07B 10-K · filed 2026-02-12 | |
| 2022-09-30 | $2.62B 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $2.62B 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $2.46B 10-Q · filed 2023-04-27 | |
| 2021-12-31 | $3.82B 10-K · filed 2025-02-19 | |
| 2021-09-30 | $3.79B 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $3.22B 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $3.00B 10-Q · filed 2022-04-29 | |
| 2020-12-31 | $3.66B 10-K · filed 2024-02-21 | |
| 2020-09-30 | $3.60B 10-Q · filed 2021-10-27 | |
| 2020-06-30 | $2.37B 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $1.70B 10-Q · filed 2021-04-30 | |
| 2019-12-31 | $2.34B 10-K · filed 2023-02-22 | |
| 2019-09-30 | $1.56B 10-Q · filed 2020-10-28 | |
| 2019-06-30 | $2.29B 10-Q · filed 2020-07-31 | |
| 2018-12-31 | $8.00B 10-K · filed 2022-02-23 | |
| 2017-12-31 | $6.54B 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |